MedImmune D5760C00001: A Phase 1 Multicenter, Open-label, Dose-escalation, and
Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI4276 in Subjects with Select HER2-expressing Advanced Solid Tumor
Brief Description
The primary objective is to assess the safety, describe the DLTs, and determine the MTD or the maximum administered dose (MAD; in the absence of exceeding the MTD) for MEDI4276 administered as a single agent in subjects with HER2-expressing advanced breast or gastric cancer refractory to standard therapy or for which no standard therapy exists.
Who may be Eligible
Please contact us for eligibility criteria.
Speciality/Disorder
Breast
Status
OPEN
Start Date
04/27/2016
IRB Number
00016397
Principal Investigator
Tan, Antoinette Roslyn
Contact Name
Tesa M Adams
For More Information, Contact Tesa M, Adams
Phone: 980-442-2335 Fax: Email: Tesa.Adams@atriumhealth.org Address:1021 Morehead Medical Drive Suite 2200 Charlotte, NC 28204